Search for other papers by Niels B Dalsgaard in
Google Scholar
PubMed
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Search for other papers by Lærke S Gasbjerg in
Google Scholar
PubMed
Search for other papers by Laura S Hansen in
Google Scholar
PubMed
Search for other papers by Dennis S Nielsen in
Google Scholar
PubMed
Search for other papers by Torben S Rasmussen in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Steno Diabetes Center Copenhagen, Gentofte, Denmark
Search for other papers by Filip K Knop in
Google Scholar
PubMed
, and Blautia genera positively associate with T2D while Bifidobacterium , Bacteroides , Faecalibacterium , Akkermansia , and Roseburia members negatively associate with and may protect against T2D ( 4 ). Acarbose is an alpha
Search for other papers by Ruixin Hu in
Google Scholar
PubMed
Search for other papers by Yanting Yuan in
Google Scholar
PubMed
Search for other papers by Chaolong Liu in
Google Scholar
PubMed
Search for other papers by Ji Zhou in
Google Scholar
PubMed
Search for other papers by Lixia Ji in
Google Scholar
PubMed
Search for other papers by Guohui Jiang in
Google Scholar
PubMed
and TNF-α, MCP-1 decreased. (27, 28, 29) Acarbose ↑Faecalibacterium , ↑Prevotella , ↑Bifidobacterium longum , ↑Lactobacillus gasseri , ↓Enterococcus faecalis , ↓Clostridium ↑Bacteroides , ↑Blautia , ↑Bifidobacterium , ↓Desulfovibrio
Search for other papers by Jonathan Hazlehurst in
Google Scholar
PubMed
Search for other papers by Bernard Khoo in
Google Scholar
PubMed
Department of Medicine, Copenhagen University Hospital – Amager and Hvidovre, Hvidovre, Denmark
Search for other papers by Carolina Brito Lobato in
Google Scholar
PubMed
Search for other papers by Ibiyemi Ilesanmi in
Google Scholar
PubMed
Search for other papers by Sally Abbott in
Google Scholar
PubMed
Search for other papers by Tin Chan in
Google Scholar
PubMed
Search for other papers by Sanesh Pillai in
Google Scholar
PubMed
Search for other papers by Kate Maslin in
Google Scholar
PubMed
Imperial College Healthcare NHS Trust, St Mary’s Hospital, London, UK
Search for other papers by Sanjay Purkayastha in
Google Scholar
PubMed
Search for other papers by Barbara McGowan in
Google Scholar
PubMed
Search for other papers by Rob Andrews in
Google Scholar
PubMed
Search for other papers by Eveleigh Nicholson in
Google Scholar
PubMed
Search for other papers by Katherine McCullough in
Google Scholar
PubMed
Search for other papers by Lorraine Albon in
Google Scholar
PubMed
Search for other papers by Rachel Batterham in
Google Scholar
PubMed
Search for other papers by Georgios K Dimitriadis in
Google Scholar
PubMed
Search for other papers by Shareen Forbes in
Google Scholar
PubMed
Search for other papers by Gavin Bewick in
Google Scholar
PubMed
Search for other papers by Tricia M-M Tan in
Google Scholar
PubMed
. Low 2.7 Sucrose for treatment of hypoglycaemia should be avoided in acarbose-treated PBH. High 2.8 People should be encouraged to exercise after bariatric surgery. A suggested approach to exercise in PBH is as follows: - They should
Search for other papers by Zhenyu Liu in
Google Scholar
PubMed
Search for other papers by Huixi Kong in
Google Scholar
PubMed
Search for other papers by Baoyu Zhang in
Google Scholar
PubMed
Before–after study ( 59 ) α-Glucosidase inhibitors Acarbose ↓ sucrose: 4.9 ± 1.0 to 5.4 ± 1.1 mg/dL sucrose + acarbose: 4.7 ± 1.3 to 4.9 ± 1.4 mg/dL 6 healthy subjects Clinical trial ( 68 ) Sulfonylureas Gliclazide ⇔ – 29
Search for other papers by Chun-feng Lu in
Google Scholar
PubMed
Search for other papers by Wang-shu Liu in
Google Scholar
PubMed
Search for other papers by Xiao-qin Ge in
Google Scholar
PubMed
Search for other papers by Feng Xu in
Google Scholar
PubMed
significantly increased ( P for trend < 0.05), whereas the percentage of females, percentage of patients using insulin, and eGFR decreased ( P for trend > 0.05). There were significant differences in the use of metformin, acarbose, insulin sensitizers and
Search for other papers by Chun-feng Lu in
Google Scholar
PubMed
Search for other papers by Xiao-qin Ge in
Google Scholar
PubMed
Search for other papers by Yan Wang in
Google Scholar
PubMed
Search for other papers by Jian-bin Su in
Google Scholar
PubMed
Search for other papers by Xue-qin Wang in
Google Scholar
PubMed
Search for other papers by Dong-mei Zhang in
Google Scholar
PubMed
Search for other papers by Feng Xu in
Google Scholar
PubMed
Search for other papers by Wang-shu Liu in
Google Scholar
PubMed
Search for other papers by Min Su in
Google Scholar
PubMed
(45.3) 45 (33.8) 0.042 Acarbose, n (%) 47 (9.6) 17 (9.2) 18 (10.6) 12 (8.8) 0.844 Insulin secretagogues, n (%) 155 (31.5) 58 (31.4) 54 (31.8) 43 (31.4) 0.996 Insulin sensitizers, n (%) 33 (6.7) 11
Department of Endocrinology, Zunyi Medical University, Zunyi, China
Search for other papers by Mengxue Yang in
Google Scholar
PubMed
Search for other papers by Bowen Sun in
Google Scholar
PubMed
Search for other papers by Jianhui Li in
Google Scholar
PubMed
Search for other papers by Bo Yang in
Google Scholar
PubMed
Search for other papers by Jie Xu in
Google Scholar
PubMed
Search for other papers by Xue Zhou in
Google Scholar
PubMed
Search for other papers by Jie Yu in
Google Scholar
PubMed
Search for other papers by Xuan Zhang in
Google Scholar
PubMed
Search for other papers by Qun Zhang in
Google Scholar
PubMed
Search for other papers by Shan Zhou in
Google Scholar
PubMed
Search for other papers by Xiaohua Sun in
Google Scholar
PubMed
antibiotics, probiotics or other medicine (such as metformin, acarbose or herbal preparations) and food that could possibly influence the intestinal flora; (4) the use of any anti-thyroid gland medicine before recruitment and (5) the existence of current
Search for other papers by Wang-shu Liu in
Google Scholar
PubMed
Search for other papers by Ling-yan Hua in
Google Scholar
PubMed
Search for other papers by Su-xiang Zhu in
Google Scholar
PubMed
Search for other papers by Feng Xu in
Google Scholar
PubMed
Search for other papers by Xue-qin Wang in
Google Scholar
PubMed
Search for other papers by Chun-feng Lu in
Google Scholar
PubMed
Search for other papers by Jian-bin Su in
Google Scholar
PubMed
Search for other papers by Feng Qi in
Google Scholar
PubMed
.117 Antidiabetic treatments Insulin treatment, n (%) 59 (23.3) 12 (14.3) 18 (20.9) 29 (34.9) 0.006 Metformin, n (%) 111 (43.9) 40(47.6) 40 (46.5) 31 (37.3) 0.340 Acarbose, n (%) 17 (6.7) 5 (6.0) 8 (9
Search for other papers by Jothydev Kesavadev in
Google Scholar
PubMed
Search for other papers by Pradeep Babu Sadasivan Pillai in
Google Scholar
PubMed
Search for other papers by Arun Shankar in
Google Scholar
PubMed
Search for other papers by Gopika Krishnan in
Google Scholar
PubMed
Search for other papers by Sunitha Jothydev in
Google Scholar
PubMed
, cardiac failure, hemochromatosis, autoimmune disorders and on systemic corticosteroids intake, were excluded. Patients with BMI >40 kg/m 2 and those using acarbose, pioglitazone or short-acting insulin analogs at the time of run-in phase were
Departments of Endocrinology, Molecular Medicine and Surgery, Metabolism and Diabetes
Search for other papers by Lisa Arnetz in
Google Scholar
PubMed
Departments of Endocrinology, Molecular Medicine and Surgery, Metabolism and Diabetes
Search for other papers by Neda Rajamand Ekberg in
Google Scholar
PubMed
Departments of Endocrinology, Molecular Medicine and Surgery, Metabolism and Diabetes
Search for other papers by Kerstin Brismar in
Google Scholar
PubMed
Departments of Endocrinology, Molecular Medicine and Surgery, Metabolism and Diabetes
Search for other papers by Michael Alvarsson in
Google Scholar
PubMed
/repa+pioglitazone 1 0 Add-on sitagliptin 2 0 Add-on SU/repa+sitagliptin 1 0 Add-on liraglutide 0 1 Add-on acarbose 1 0 Add-on, in addition to metformin therapy; HOMA-IR, homeostatic model assessment of insulin resistance. All pati ents were middle aged, although men